Zobrazeno 1 - 10
of 351
pro vyhledávání: '"Irmeli Lautenschlager"'
Autor:
Tarchini, Giorgio
Publikováno v:
Clinical Infectious Diseases, 2015 Feb 01. 60(3), 496-497.
Externí odkaz:
https://www.jstor.org/stable/26362938
Autor:
Irmeli Lautenschlager, Minna Koskenvuo, Adam Alexandersson, Mervi Taskinen, Pasi Huttunen, Anette Tiderman, Mitja Lääperi, Veli-Jukka Anttila, Ulla M. Saarinen-Pihkala
Publikováno v:
Infectious Diseases. 51:772-778
Background: Viral infections are a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Although immune suppression plays a central role, the literat...
Autor:
Irmeli Lautenschlager, Ilkka Helanterä, Fernanda Ortiz, Marko Lempinen, Juulia Räihä, Laura Mannonen, Raisa Loginov
Publikováno v:
Transplant infectious disease : an official journal of the Transplantation SocietyREFERENCES. 23(4)
Cytomegalovirus continues to be a concern after transplantation despite prophylaxis regimens. Our aim was to analyse post-prophylaxis primary cytomegalovirus infections among kidney transplant recipients after 6-month valganciclovir prophylaxis and t
Autor:
Elli-Maija Ukonmaanaho, Adam Alexandersson, Irmeli Lautenschlager, Minna Koskenvuo, Laura Mannonen, Mervi Taskinen
Publikováno v:
Infectious diseases (London, England). 53(3)
Dear Editor, There are a limited number of reports on the effect of immune reconstitution on the incidence and outcome of respiratory viral infections after paediatric allogenic haematopoietic stem...
Publikováno v:
Liver International. 38:210-223
Human herpesvirus 6 (HHV-6A and HHV-6B) can cause primary infection or reactivate from latency in liver transplant recipients, which can result in a variety of clinical syndromes, including fever, hepatitis, encephalitis and higher rates of graft dys
Autor:
Hans H. Hirsch, Juuso Tainio, Hannu Jalanko, Marion Wernli, Irmeli Lautenschlager, Fabian H. Weissbach, Elisa Ylinen, Jenni Miettinen
Publikováno v:
Pediatric Transplantation. 23
BKPyV is widely recognized in KTRs, but little is known about rates of primary and secondary JCPyV exposure in pediatric KTRs. We evaluated JCPyV exposure in pediatric KTRs using antibody responses in the first 12 months post-transplant. Of 46 childr
Autor:
Rainer Gosert, Hans H. Hirsch, Nina Khanna, Irmeli Lautenschlager, Ilkka Helanterä, Klaudia Naegele, Stefan Schaub, Katia Bir, Raisa Loginov
Background Cytomegalovirus (CMV) management post-transplantation relies on quantification in blood, but inter-laboratory and inter-assay variability impairs commutability. An international multicenter study demonstrated that variability is mitigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d8a3789907e7a78e3c3c651db60ea86
http://hdl.handle.net/10138/301105
http://hdl.handle.net/10138/301105
Autor:
Timo Jahnukainen, Lars Paulin, Hanna Seppälä, Petri Auvinen, Ilkka Helanterä, Irmeli Lautenschlager, Pia Laine, Eeva Auvinen
Publikováno v:
The Journal of infectious diseases. 216(8)
Background JC polyomavirus (JCPyV) is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCPyV-associated nephropathy (JCPyVAN). Whereas progressive multifocal leukoencephalopathy of the brain is caused by rearra
Autor:
Elina Virtanen, Pia Laine, Ilkka Helanterä, Irmeli Lautenschlager, Lars Paulin, Petri Auvinen, Hanna Seppälä, Eeva Auvinen, Laura Mannonen
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 102
Background BK polyomavirus (BKPyV) infection is a common asymptomatic viral infection in the general population. Severe complications are seen in immunocompromised individuals, such as polyomavirus-associated nephropathy (PyVAN) in renal transplant r
Autor:
Timo Jahnukainen, Alexis Dumoulin, Irmeli Lautenschlager, Eeva Auvinen, Laura Mannonen, Hans H. Hirsch, Hannu Jalanko, Piotr Kardas, Jouko Lohi
Publikováno v:
American Journal of Transplantation. 14:2887-2892
A 15-year-old boy with a posterior urethral valve received a deceased donor kidney transplant (KT) in March 2011. Basiliximab induction followed by tacrolimus-based triple medication was used as immunosuppression. Eleven months after KT, the graft fu